WuXi Advanced Therapies (WuXi ATU) announced the opening on November 9^th of their new cell and gene therapy testing facility that is located in the Philadelphia Navy Yard. The new facility, which includes 140,000 square feet of laboratory space, will further enhance the company’s Contract Testing, Development and Manufacturing Organization (CTDMO) business model by tripling the company’s previous testing capacity, meeting the increasing needs of customers in cell and gene therapy industry. The new state-of the-art facility is an expansion of WuXi ATU’s existing Navy Yard Campus, which opened in 2020. This addition will strengthen the existing analytical development and testing capacity and capability.
 
As a CTDMO with global operations, WuXi ATU’s business model integrates powerful testing capabilities with its advanced therapies’ process development and manufacturing platforms, such as TESSA technology for AAV manufacturing and XLenti stable solutions for lentiviral manufacturing. This allows all assay development, biosafety, viral clearance and product release testing to be completed in-house, shortening customers’ timelines for the approval of advanced therapies. WuXi ATU has supported more than 1,700 customer submissions for biosafety testing through industry-leading testing and analytical assay development experience, enabling the delivery of more effective and accessible advanced therapies to patients.